Evidence map›Paper›PMID 34275536›Full record

ArticleJournal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia2021

Evolution of our understanding of MS-COVID-19 interactions and concerns for vaccination.

Sanjiti Podury, Erum Khan, Medha Tandon, Shruti Jaiswal, Shitiz Sriwastava

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 94% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Sanjiti PoduryArmy College of Medical Sciences, India.
Erum KhanB.J. Medical College and Civil Hospital, Ahmedabad, India.
Medha TandonUniversity of Pittsburgh Medical Center, Pittsburgh, PA, United States.
Shruti JaiswalWest Virginia Clinical and Translational Science Institute, West Virginia University, Morgantown, WV, United States.
Shitiz SriwastavaDepartment of Neurology, Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV, United States; West Virginia Clinical and Translational Science Institute, West Virginia University, Morgantown, WV, United States. Electronic address: shitiz.sriwastava@hsc.wvu.edu.
B.J. Medical College · INBlanchette Rockefeller Neurosciences Institute · USUniversity of Pittsburgh Medical Center · USWest Virginia University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As the news of approval of COVID-19 vaccination emerge, neurologists across the globe ponder upon whether to use immunotherapies in patients with Multiple Sclerosis (MS). This paper highlights the mechanism of various disease modifying therapies (DMTs) as well as the recently approved Pfizer and Moderna vaccines for COVID-19 as well as guidelines as introduced by National Multiple Sclerosis Society. As their mechanisms counteract each other at the molecular level, we believe further evidence and data might lay the foundation to formulate much needed recommendations for the usage of these medications while vaccinating MS patients on DMTs.

Indexed as

COVID-19 VaccinesVaccinationCOVID-19HumansImmunotherapyMultiple SclerosisCOVID-19 VaccinesCOVID-19COVID-19 vaccineDisease modifying therapiesMultiple Sclerosis

Identifiers

PMID34275536
PMCPMC8166521
OpenAlexW3168379781

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.